Farsoon Technologies (SHA:688433) said its new drug application for selevirimimab injection was accepted by China's medical products administrator.
The injection, which is intended for post-exposure passive immunization against suspected rabies virus exposure, has met the primary efficacy endpoint in phase three clinical trials, according to a Wednesday filing with the Shanghai bourse.
The biopharmaceutical company's shares closed 3% lower Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments